Cargando…
Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Anti-spike monoclonal antibody therapy may be effective for pregnant women with coronavirus disease 2019 (COVID-19).
Autores principales: | Thilagar, Bright P., Ghosh, Aditya K., Nguyen, Jerome, Theiler, Regan N., Wick, Myra J., Hurt, Ryan T., Razonable, Raymund R., Ganesh, Ravindra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936149/ https://www.ncbi.nlm.nih.gov/pubmed/35026789 http://dx.doi.org/10.1097/AOG.0000000000004700 |
Ejemplares similares
-
Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022) -
Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for
Mild to Moderate Coronavirus Disease-2019
por: Razonable, Raymund R, et al.
Publicado: (2022) -
Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease
por: Di Lullo, Luca, et al.
Publicado: (2015) -
Proliferative glomerulonephritis with monoclonal immunoglobulin in renal allografts
por: Al-Rabadi, Laith, et al.
Publicado: (2015) -
Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People
por: Afshar, Yalda, et al.
Publicado: (2020)